ERVW-1 and COVID-19: The T-cell epitope-based peptide vaccine was designed for COVID-19 using the envelope protein as an immunogenic target; nevertheless, the proposed vaccine rapidly needs to be validated clinically ensuring its safety and immunogenic profile to help stop this epidemic before it leads to devastating global outbreaks.